🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with estimates suggesting more than 82 million infections annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the reality of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval signifies a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Results and Worldwide Availability

According to results published in a major medical journal, the new drug cured more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which combines an injection and a pill. The research included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Doctors on the front lines have expressed positive views. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea globally.